Vascular Biogenics Ltd.

NasdaqCM:VBLT Stock Report

Market Cap: US$12.1m

Vascular Biogenics Past Earnings Performance

Past criteria checks 0/6

Vascular Biogenics's earnings have been declining at an average annual rate of -14.9%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been declining at an average rate of 67.7% per year.

Key information

-14.9%

Earnings growth rate

5.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-67.7%
Return on equity-82.9%
Net Margin-3,317.0%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

VBL Therapeutics receives non-compliance letter from Nasdaq

Sep 01

VBL Therapeutics GAAP EPS of -$0.12

Aug 15

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

Jul 19

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

May 18
Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Sep 03

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

Mar 17
How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

Jan 28
How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

VBL Therapeutics expands the ovarian cancer trial in Europe

Dec 29

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Dec 24
Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 19
Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

VBL Therapeutics EPS beats by $0.01, misses on revenue

Nov 16

Revenue & Expenses Breakdown

How Vascular Biogenics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:VBLT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 230-16116
31 Mar 231-251214
31 Dec 221-321222
30 Sep 221-381326
30 Jun 221-351125
31 Mar 221-34925
31 Dec 211-30823
30 Sep 211-28622
30 Jun 211-27622
31 Mar 211-25620
31 Dec 201-24520
30 Sep 201-23618
30 Jun 201-22617
31 Mar 201-21616
31 Dec 191-19615
30 Sep 191-18515
30 Jun 191-18516
31 Mar 191-17514
31 Dec 181-20615
30 Sep 1814-10617
30 Jun 1814-11617
31 Mar 1814-12718
31 Dec 1714-10618
30 Sep 170-21616
30 Jun 170-18514
31 Mar 170-16413
31 Dec 160-16412
30 Sep 160-14411
30 Jun 160-17413
31 Mar 160-17413
31 Dec 150-15411
30 Sep 150-17312
30 Jun 150-15210
31 Mar 150-15211
31 Dec 140-17211
30 Sep 140-18212
31 Dec 130-17214

Quality Earnings: VBLT is currently unprofitable.

Growing Profit Margin: VBLT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VBLT is unprofitable, and losses have increased over the past 5 years at a rate of 14.9% per year.

Accelerating Growth: Unable to compare VBLT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VBLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).


Return on Equity

High ROE: VBLT has a negative Return on Equity (-82.94%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/17 20:03
End of Day Share Price 2023/10/16 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vascular Biogenics Ltd. is covered by 8 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gbolahan Amusa BenzChardan Capital Markets, LLC
Alethia YoungDeutsche Bank
Etzer DaroutGuggenheim Securities, LLC